SCHEMBL213770

SCHEMBL213770

O=CC[C@@H](O)[C@H](O)[C@H](O)COP(=O)(O)O

nearest known ligand 0.67

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.58
PGD P52209 3/20 0.48
PGK1 P00558 1/20 0.42
PGK2 P07205 1/20 0.42
LPAR5 Q9H1C0 1/20 0.33
SGPL1 O95470 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3507132 1.00 MPI (0.58) MPIPGDPGK1PGK2LPAR5
SCHEMBL20553435 1.00 MPI (0.58) MPIPGDPGK1PGK2LPAR5
SCHEMBL1353551 1.00 MPI (0.58) MPIPGDPGK1PGK2LPAR5
SCHEMBL4594608 0.88 MPI (0.62) MPIPGDPGK1PGK2LPAR5
SCHEMBL20857032 0.88 MPI (0.62) MPIPGDPGK1PGK2LPAR5
SCHEMBL139868 0.88 MPI (0.62) MPIPGDPGK1PGK2LPAR5
SCHEMBL2234036 0.86 MPI (0.60) MPIPGDPGK1PGK2LPAR5
Cetyl Alcohol SCHEMBL3167243 0.84 LPAR5 (0.46) MPILPAR5SGPL1
Acetaldehyde SCHEMBL22264056 0.83 MPI (0.56) MPIPGDPGK1PGK2LPAR5
SCHEMBL16416132 0.81 PGD (0.61) MPIPGDPGK1PGK2LPAR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 880 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4679087-A1 BIOMARKER AND USE THEREOF MEIJI CO., LTD (JP) 2026-01-14 EP claimed
WO-2025134122-A1 DIAGNOSTIC AGENTS AND USES THEREOF HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2025-06-26 WO claimed
WO-2024190663-A1 BIOMARKER AND USE THEREOF 株式会社明治 2024-09-19 WO claimed
US-11723934-B2 Compositions and methods for the induction of CD8+ T-cells KEIO UNIVERSITY (JP) 2023-08-15 US claimed
US-20220023207-A1 DRUG DELIVERY SYSTEM USING SOLUTION KYOTO UNIVERSITY (JP) 2022-01-27 US claimed
EP-3888693-A1 DRUG DELIVERY SYSTEM USING SOLUTION Kyoto University (JP) 2021-10-06 EP claimed
CN-113195003-A Drug delivery system using solution 国立大学法人京都大学 2021-07-30 CN claimed
US-20170281772-A1 A NEURAL SUBSTRATE FOR SUGAR PREFERENCE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-10-05 US claimed
US-8604278-B2 Expression cassettes for transgenic expression of nucleic acids SUNGENE GMBH & CO. KGAA (DE) 2013-12-10 US claimed
US-20110289622-A1 EXPRESSION CASSETTES FOR TRANSGENIC EXPRESSION OF NUCLEIC ACIDS SUNGENE GMBH & CO. KGAA (DE) 2011-11-24 US claimed
WO-2003008596-A2 EXPRESSION CASSETTES FOR TRANSGENICALLY EXPRESSING SELECTION MARKERS SUNGENE GMBH & CO. KGAA (DE) 2003-01-30 WO claimed
WO-2003006660-A1 EXPRESSION CASSETTES FOR THE TRANSGENIC EXPRESSION OF NUCLEIC ACIDS SUNGENE GMBH & CO. KGAA (DE) 2003-01-23 WO claimed
US-6472201-B1 GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES BIOLOG, INC. 2002-10-29 US claimed
EP-0973921-B1 2-DEOXYGLUCOSE-6-PHOSPHATE (2-DOG-6-P) PHOSPHATASE DNA SEQUENCES AS SELECTION MARKERS IN PLANTS IPK GATERSLEBEN (DE) 2001-09-05 EP claimed
EP-0973921-A1 2-DEOXYGLUCOSE-6-PHOSPHATE (2-DOG-6-P) PHOSPHATASE DNA SEQUENCES AS SELECTION MARKERS IN PLANTS IPK Gatersleben (DE) 2000-01-26 EP claimed
WO-1998045456-A1 2-DEOXYGLUCOSE-6-PHOSPHATE (2-DOG-6-P) PHOSPHATASE DNA SEQUENCES AS SELECTION MARKERS IN PLANTS IPK GATERSLEBEN (DE) 1998-10-15 WO claimed
EP-0870836-A1 2-Deoxyglucose-6-Phosphate (2-DOG-6-P) Phosphatase DNA sequences for use as selectionmarker in plants IPK Gatersleben (DE) 1998-10-14 EP claimed
EP-0508346-B1 Process for the enzymatic synthesis of 2-desoxy-bêta-D-galactosides HOECHST AG (DE) 1996-07-17 EP claimed
US-5264352-A The enzyme galactosyl transferase catalyze the transfer of 2-deoxygalactose residue from uridine-5-diphospho-2-deoxy-D-galactose to N-acetyl-glucosamien or aspartyl-N-acetyl glucosamine HOECHST AKTIENGESELLSCHAFT (DE) 1993-11-23 US claimed
EP-0508346-A2 Process for the enzymatic synthesis of 2-desoxy-bêta-D-galactosides HOECHST AKTIENGESELLSCHAFT (DE) 1992-10-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023207-A1 DRUG DELIVERY SYSTEM USING SOLUTION PDIA6, PDIA5, DUS2 MPI 931/4885PGD 1334/4885PGK1 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.